TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 342318
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 7 log EID50/dose
Study: 31728681
Drug: Resistant dextrin
Normalized name: wheat dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant dextrin (10 g/day)
Study: 29114781
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation of once-weekly isoniazid and rifapentine
Study: 29114781
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of once-weekly isoniazid and rifapentine
Study: 29114781
Drug: Self-administration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration with reminders of once-weekly isoniazid and rifapentine
Study: 25457496
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (RT with hormonal therapy, dosage ≥69Gy)
Study: 25457496
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (RT with hormonal therapy)
Study: 18565968
Drug: PRAV+IRB (pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAV+IRB (pravastatin 40 mg/day + irbesartan 300 mg/day)
Study: 18565968
Drug: PRAV (pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAV (pravastatin 40 mg/day)
Study: 10730982
Drug: Oxytocin (1.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (1.9 mg/d) continuous infusion from Days 14 to 26 after estrus
Study: 8774294
Drug: Split-dose hMG
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose hMG (150 IU twice daily)
Study: 8774294
Drug: Single-dose hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose hMG (300 IU once daily)
Study: 8774294
Drug: Split-dose hMG
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose hMG
Study: 8774294
Drug: Single-dose hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose hMG
Study: 1590574
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at 15 mg/kg body weight per hour for 10 min after induction, then reduced to 6 mg/kg body weight per hour
Study: 1590574
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg before induction with propofol at similar dosage to group I
Study: 1590574
Drug: Fentanyl 0.1
Normalized name: fentanyl 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.1 mg before induction with propofol at an infusion rate of 6 mg/kg body weight from the beginning
Study: 26453188
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received only a list of substance use treatment resources)
Study: 23571174
Drug: HPV16/18 bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16/18 bivalent vaccine
Study: 12740676
Drug: Lower molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower molecular weight hyaluronic acid plus physical therapy
Study: 12740676
Drug: Higher molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher molecular weight hyaluronic acid plus physical therapy
Study: 9286743
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (1 mg.kg‐1.day‐1) for 28 days
Study: 3948042
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intramuscular ketamine (Group I)
Study: 3948042
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg epidural ketamine (Group II)
Study: 3948042
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg epidural ketamine (Group III)
Study: 29462225
Drug: Efinaconazole 10%
Normalized name: EFINACONAZOLE 10% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efinaconazole 10% solution, once-daily for 48 weeks
Study: 25834964
Drug: Etomidate and
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etomidate and fentanyl (0.25 mg/kg etomidate, 1.30 μg/kg fentanyl)
Study: 25834964
Drug: Ketamine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1.25 mg/kg)
Study: 18627363
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg zidovudine and 150 mg lamivudine B.I.D. for 6 months
Study: 16129365
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance chemotherapy with cyclophosphamide (n=146)
Study: 16129365
Drug: Oral maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral maintenance chemotherapy
Study: 10791213
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 treatment (PG group; n = 19)
Study: 8778905
Drug: buspirone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (30 mg PO)
Study: 6143664
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Metoprolol (beta‐1‐selective blockade)
Study: 6143664
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Bupranolol (non‐selective beta‐blockade)
Study: 26011816
Drug: Mitiglinide/Voglibose (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitiglinide/Voglibose (fixed-dose combination of mitiglinide 10 mg and voglibose 0.2 mg)
Study: 26011816
Drug: Glimepiride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (0.5 mg)
Study: 17672383
Drug: Lorazepam (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (1.0 and 2.0 mg/70 kg, orally administered)
Study: 17672383
Drug: Scopolamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.25 and 0.50 mg/70 kg, subcutaneously administered)
Study: 10468801
Drug: Cyclosporin (Neoral)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Neoral) at a dose of 2.5 mg/kg daily, increased to a maximum of 5 mg/kg daily for a maximum of 12 weeks, followed by either abrupt cessation or tapering off by 1 mg/kg weekly.
Study: 10468801
Drug: Cyclosporin (Neoral)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Neoral) treatment courses
Study: 10468801
Drug: Cyclosporin (Neoral)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin (Neoral) treatment
Study: 2286467
Drug: Fosfomycin trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin trometamol 3 g single dose
Study: 2286467
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg b.i.d. for seven days
Study: 27658661
Drug: B&O suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: B&O suppository (15 mg/30 mg)
Study: 23958473
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day sphingomyelin (SM) for 14 days
Study: 19242031
Drug: Daily IFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Study: 19242031
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Study: 19242031
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly IFA supplementation (100 mg elemental iron + 0.5 mg folic acid)
Study: 17900401
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bupivacaine 0.5% intrathecally plus 500 ml Ringer lactate solution (group B)
Study: 17900401
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bupivacaine 0.5% plus 25 mug fentanyl plus 500 ml Ringer lactate solution (group F)
Study: 17900401
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously (group G)
Study: 17900401
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg bupivacaine 0.5% plus 25 mug fentanyl intrathecally plus 500 ml Gelofusine intravenously plus tight wrapping of the lower extremities with an Esmarch bandage (group E)
Study: 17108343
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa targeted to achieve a hemoglobin level of 13.5 g/dL
Study: 17108343
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa targeted to achieve a hemoglobin level of 11.3 g/dL
Study: 6804114
Drug: Pressurized aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressurized aerosol formulation of sodium cromoglycate (8 mg/day)
Study: 6804114
Drug: Standard sodium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard sodium cromoglycate powder (80 mg/day)
Study: 29907780
Drug: Electrical Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical Stimulation (ES) prior to hand function training, 40 minutes before each session, twice a week for 8 weeks
Study: 27153942
Drug: Psychoeducative Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducative Group Therapy (PeGT)
Study: 24776218
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid 10 mg/kg body weight
Study: 24776218
Drug: placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo saline 5 ml
Study: 15629610
Drug: WBRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT plus TMZ (75 mg/m²/d) plus two cycles of TMZ (200 mg/m²/d for 5 days)
Study: 10369195
Drug: Chlorambucil in
Normalized name: Product containing chlorambucil in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil in conjunction with oral steroids
Study: 10369195
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and oral steroids
Study: 10369195
Drug: Oral high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral high-dose corticosteroids
Study: 7759773
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIG) 400 mg/Kg every fourth week
Study: 7759773
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir 800 mg twice a day for one week every month
Study: 1969833
Drug: Sufotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufotidine 600 mg bd
Study: 20329618
Drug: Wuzi Yanzong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzi Yanzong Pill (WYP)
Study: 12072067
Drug: Topical minoxidil
Normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical minoxidil 2% (2 mL day-1) plus combined oral contraceptive
Study: 12072067
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (52 mg day-1) plus ethinyl oestradiol (35 microg for 20 of every 28 days)
Study: 10152782
Drug: Ceftazidime 2
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2 g q8h
Study: 2677916
Drug: Conservative functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative functional treatment with orthotic support
Study: 2677915
Drug: Operative functional
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Operative functional treatment
Study: 31116262
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction (MBSR) combined with music therapy (MT)
Study: 28270029
Drug: Waitlist-control group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist-control group (no treatment)
Study: 25874853
Drug: Sildenafil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (2 × 20 mg)
Study: 24238512
Drug: Famitinib (13-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib (13-30 mg once daily)
Study: 24238512
Drug: Famitinib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famitinib (25 mg once daily)
Study: 22035131
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg/losartan 50 mg
Study: 22035131
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/losartan 50 mg
Study: 10350494
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing 5% flurbiprofen
Study: 10350494
Drug: Control formulation
Normalized name: nut.tx, weight loss-control formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control formulation (0% flurbiprofen)
Study: 7851558
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (CDDP 66 mg/m2 x 1, ADM 26 mg/m2 x 1, UFT 8 mg/kg/day for 6 months)
Study: 7851558
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy (after adjusting for pN)
Study: 1779485
Drug: 0.12% UF-021,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% UF-021, twice daily for 4 weeks
Study: 31060476
Drug: High L-Theanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High L-Theanine tea
Study: 29653550
Drug: 1.6 g
Normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 g of Mecasin
Study: 29653550
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g of Mecasin
Study: 29653550
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with 100 mg of riluzole
Study: 28199752
Drug: Subcostal TAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcostal TAP block in combination with general anesthesia
Study: 26233509
Drug: JNJ-40346527 100
Normalized name: JNJ-40346527
DrugBank: JNJ-40346527 (DB12504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-40346527 100 mg
Study: 24142206
Drug: Odanacatib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib (3 once-weekly doses of 50 mg) co-administered with warfarin (30 mg)
Study: 21134325
Drug: Calcium HMB
Normalized name: calcium HMB/vitamin D3 0.5 gram-2.08 mcg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium HMB (CaHMB) - gelatin capsule, 1 g
Study: 21134325
Drug: HMB free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB free acid gel swallowed (FASW)
Study: 21134325
Drug: HMB free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB free acid gel held sublingual for 15 s then swallowed (FASL)
Study: 18211121
Drug: Apricitabine 200
Normalized name: emtricitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine 200 mg twice daily
Study: 18211121
Drug: Apricitabine 400
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 400 mg twice daily
Study: 18211121
Drug: Apricitabine 600
Normalized name: efavirenz 600 MG / emtricitabine 200 MG / tenofovir disoproxil fumarate 300 MG [Atripla]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine 600 mg twice daily
Study: 18211121
Drug: Apricitabine 800
Normalized name: cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG [Symtuza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine 800 mg twice daily
Study: 18211121
Drug: Apricitabine 800
Normalized name: cobicistat 150 MG / darunavir 800 MG / emtricitabine 200 MG / tenofovir alafenamide 10 MG [Symtuza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apricitabine 800 mg once daily
Study: 18211121
Drug: Apricitabine 1200
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 1200 mg once daily
Study: 16629939
Drug: Cernevit (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernevit (vitamin preparation with glycocholic acid)
Study: 16629939
Drug: Control vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vitamin supplements
Study: 15323062
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg)/Indapamide (0.625 mg)
Study: 9032174
Drug: Amino acids
Normalized name: Amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acids and related compounds in bronchoalveolar lavage (BAL) fluid
Study: 8500246
Drug: No warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No warfarin treatment
Study: 3548616
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin at midnight before the operation
Study: 3548616
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin and 75 mg of dipyridamole at midnight and an additional 75 mg of dipyridamole at 6 AM
Study: 29223912
Drug: Maternal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal buprenorphine dose
Study: 18701886
Drug: Thrice‐weekly urine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice‐weekly urine tests for opiates, cocaine, and benzodiazepines
Study: 12846271
Drug: HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT group (n = 151) received a sequential combination of 2 mg estradiol valerate and 1 mg cyproterone acetate with or without vitamin D3 (100-300 IU) + 93 mg calcium as lactate/day
Study: 12846271
Drug: Non-HRT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HRT group (n = 180) received 93 mg calcium alone or in combination with vitamin D3 (100-300 IU/day)
Study: 9684663
Drug: Cisapride 20
Normalized name: cisapride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 20 mg
Study: 1671346
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous metoprolol
Study: 29439773
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel with 5% potassium nitrate and 5% glutaraldehyde
Study: 29439773
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control gel
Study: 21339541
Drug: L-ornithine-L-aspartate (LOLA)
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate (LOLA) 3 x 6 g/d for 2 weeks
Study: 15557360
Drug: Patient partnership
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient partnership intervention (n = 107) received drug safety information and their medication list
Study: 15557360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 102) received drug safety information only
Study: 11567990
Drug: Filgrastim (G-CSF)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (G-CSF) alone for 4 days at 10 microg/kg per day (arm A)
Study: 11567990
Drug: Cyclophosphamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (5 g/m(2)) and G-CSF at 10 microg/kg per day until hematologic recovery (arm B)
Study: 31128336
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment with trough concentrations greater than 23.1 mg/L at week 2
Study: 31128336
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment with trough concentrations greater than 10.0 mg/L at week 6
Study: 31128336
Drug: Infliximab maintenance
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab maintenance therapy with trough concentrations greater than 10.6 mg/L
Study: 31128336
Drug: Low fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fecal concentrations of calprotectin during therapy
Study: 31128336
Drug: Persistent increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistent increase in fecal concentration of calprotectin despite dose escalation
Study: 31128336
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with antibodies to infliximab
Study: 29886103
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg/12h
Study: 20932651
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) with concurrent temozolomide (TMZ) chemotherapy, 60 Gy total dose, escalating from 3 Gy/fraction to 6 Gy/fraction, concurrent TMZ at 75 mg/m²/d for 28 days, adjuvant TMZ at 150-200 mg/m²/d for 5 days every 28 days.
Study: 16196417
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4.5 g/d for the first 4 months of lactation)
Study: 9542208
Drug: Colony-stimulating factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colony-stimulating factors (G-CSF and GM-CSF) as adjunctive care
Study: 7651658
Drug: nalbuphine 10
Normalized name: nalbuphine 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 10 mg intravenously
Study: 7651658
Drug: meperidine 50
Normalized name: meperidine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 50 mg intravenously